ArticleApoptosis : an international journal on programmed cell death2025
Novel L-type chiral metal(II) complexes inhibit breast cancer growth through synergistic effects of anti-angiogenesis, anti-inflammatory, apoptosis induction and cuproptosis.
Article in Apoptosis : an international journal on programmed cell death, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early Transition Metal-Based Antitumor Complexes.Chemistry, an Asian journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Breast cancer ranks first among female malignant tumors and is the largest cancer worldwide. Recently, research on chiral metal-based complexes for cancer treatment has significantly increased. This study synthesized an L-copper(II) complex Cu-1 and a pair of chiral nickel(II) complexes Ni-1 (L-type) and Ni-2 (D-type). The antiproliferative activities of Cu-1, Ni-1, and Ni-2 against female malignant tumor cells (MCF-7, MDA-MB-231, SKOV3, Hela) were evaluated. Among them, the L-type complexes Cu-1 and Ni-1 exhibited superior bioactivity compared to the D-type Ni-2. Further mechanistic studies demonstrated that Cu-1 and Ni-1 could effectively inhibit the growth of MCF-7 cells. Additionally, in vivo experiments in nude mice verified that Cu-1 could exert anti-tumor effects through the synergistic action of multiple pathways. In summary, Cu-1 and Ni-1 possess multiple functions including anti-tumor angiogenesis, anti-inflammatory, apoptosis, and copper-induced death, providing theoretical reference for the development of breast cancer drugs.
Indexed as
Identifiers
40715874What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.